Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Drug companies 'not happy' that drug prices 'are going down,' Trump tweets » 10:00
08/13/20
08/13
10:00
08/13/20
10:00
JNJ

Johnson & Johnson

$148.16 /

-1.5 (-1.00%)

, LLY

Eli Lilly

$151.07 /

-0.04 (-0.03%)

, MRK

Merck

$82.53 /

-0.19 (-0.23%)

, PFE

Pfizer

$38.03 /

-0.31 (-0.81%)

, SNY

Sanofi

$51.33 /

-0.55 (-1.06%)

, AZN

AstraZeneca

$56.22 /

+0.37 (+0.66%)

, GSK

GlaxoSmithKline

$41.37 /

+0.1878 (+0.46%)

, NVS

Novartis

$85.50 /

+0.575 (+0.68%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$63.19 /

-0.44 (-0.69%)

President Donald Trump…

President Donald Trump tweeted: "Drug companies, which are being forced by me to substantially reduce Drug Prices, are taking $millions in ads saying I want to increase Medicare Primiums. Wrong, just the opposite! These ads show DRUG PRICES ARE GOING DOWN, and they are not happy! False advertising!" Large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link

ShowHide Related Items >><<
SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
MRK Merck
$82.53 /

-0.19 (-0.23%)

08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
PFE Pfizer
$38.03 /

-0.31 (-0.81%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
SNY Sanofi
$51.33 /

-0.55 (-1.06%)

08/10/20 SVB Leerink
Principia Biopharma price target raised to $112 from $80 at SVB Leerink
07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

08/12/20 UBS
GlaxoSmithKline price target lowered to 1,800 GBp from 1,920 GBp at UBS
07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
NVS Novartis
$85.50 /

+0.575 (+0.68%)

08/12/20 JPMorgan
Novartis price target lowered to CHF 82 from CHF 84 at JPMorgan
07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

SNY Sanofi
$51.33 /

-0.55 (-1.06%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

Hot Stocks
Novocure announces Wilco Groenhuysen as COO, other leadership promotions » 08:36
08/13/20
08/13
08:36
08/13/20
08:36
NVCR

Novocure

$75.10 /

+0.52 (+0.70%)

, PFE

Pfizer

$38.34 /

+0.54 (+1.43%)

Novocure (NVCR) announced…

Novocure (NVCR) announced an expansion of its executive leadership team, effective September 1. After eight years of service as CFO, Wilco Groenhuysen has been appointed to an expanded COO role responsible for the general and administrative management of the company. He will also assume responsibility for the strategic and operational leadership of Novocure's supply chain, warehousing and distribution, quality assurance and information technology operations. Groenhuysen is tasked to ensure organizational readiness in anticipation of the completion of four Phase 3 clinical trials over the next few years. Ashley Cordova has been promoted to CFO and will assume responsibility for the oversight of Novocure's global financial operations, including financial reporting, financial planning and analysis, treasury, tax, and investor relations. In her new role, Cordova will report directly to Asaf Danziger, Novocure's CEO. Cordova has played a role in leading multiple financial functions for Novocure with increasing responsibilities since she joined as director of global treasury in 2014. Prior to joining Novocure, Ms. Cordova served in various financial roles at Pfizer (PFE). Frank Leonard has been promoted to chief development officer, a newly created executive role with responsibility for engineering, product development, business development and the overall strategic and operational leadership of Novocure's innovation platforms. In his new role, Leonard will report directly to Danziger. Leonard joined Novocure in 2010 to help prepare the company for the commercial launch of Optune. In this role, he established Novocure's health policy and business development groups, and additionally led various finance functions. Prior to joining Novocure, Leonard was a venture capital investor focused on high-impact medical technologies.

ShowHide Related Items >><<
PFE Pfizer
$38.34 /

+0.54 (+1.43%)

NVCR Novocure
$75.10 /

+0.52 (+0.70%)

NVCR Novocure
$75.10 /

+0.52 (+0.70%)

07/31/20 Mizuho
Novocure price target raised to $84 from $82 at Mizuho
07/30/20 Piper Sandler
Novocure price target upped to $89 at Piper Sandler after 'Q2 full of positives'
07/22/20 Piper Sandler
Novocure remains 'clear top idea' at Piper Sandler
07/15/20 Piper Sandler
Novocure remains top idea after Merck collaboration at Piper Sandler
PFE Pfizer
$38.34 /

+0.54 (+1.43%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
PFE Pfizer
$38.34 /

+0.54 (+1.43%)

NVCR Novocure
$75.10 /

+0.52 (+0.70%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

NVCR Novocure
$75.10 /

+0.52 (+0.70%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

Hot Stocks
Akcea Therapeutics' Waylivra new pricing and reimbursement approved in Germany » 07:12
08/13/20
08/13
07:12
08/13/20
07:12
AKCA

Akcea Therapeutics

$11.40 /

-0.12 (-1.04%)

Akcea Therapeutics…

Akcea Therapeutics announced that the German Association of Statutory Sick Funds has agreed upon new pricing and reimbursement of Waylivra as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome - FCS - and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. Waylivra has been commercially available in Germany since August 15, 2019. As part of reimbursement and market access protocol in Germany, Akcea was required to renegotiate the Waylivra launch price 12 months after first commercialization, which will go into effect on August 15. FCS is a debilitating genetic disease caused by impaired function of the enzyme lipoprotein lipase, which results in significant risk and disease burden. It is estimated that there are between 3,000 to 5,000 people living with FCS worldwide.

ShowHide Related Items >><<
AKCA Akcea Therapeutics
$11.40 /

-0.12 (-1.04%)

AKCA Akcea Therapeutics
$11.40 /

-0.12 (-1.04%)

01/22/20 Stifel
Akcea LICA data look 'solid,' as expected, says Stifel
10/08/19 BMO Capital
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
10/07/19 Stifel
Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel
10/07/19
Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo
AKCA Akcea Therapeutics
$11.40 /

-0.12 (-1.04%)

Yesterday
Conference/Events
Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call » 11:45
08/12/20
08/12
11:45
08/12/20
11:45
PFE

Pfizer

$38.34 /

+0.54 (+1.43%)

, MRK

Merck

$82.46 /

+1.51 (+1.87%)

, ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

, PCVX

Vaxcyte

$37.53 /

-0.62 (-1.63%)

, SNY

Sanofi

$52.00 /

+1.19 (+2.34%)

Large Cap & Biopharma…

Large Cap & Biopharma Analysts Chen & Kim, along with Dr. Arnold Lentnek, Medical Director at Infectious Disease Medical Practice of NY, debate which company will have the best-in-class next-generation pneumococcal conjugate vaccines franchise on an Analyst/Industry conference call to be held on August 19 at 1 pm.

ShowHide Related Items >><<
SNY Sanofi
$52.00 /

+1.19 (+2.34%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

PCVX Vaxcyte
$37.53 /

-0.62 (-1.63%)

MRK Merck
$82.46 /

+1.51 (+1.87%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
MRK Merck
$82.46 /

+1.51 (+1.87%)

08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
12/05/19 JPMorgan
Audentes Therapeutics downgraded to Neutral from Overweight at JPMorgan
PCVX Vaxcyte
$37.53 /

-0.62 (-1.63%)

07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
07/07/20
Fly Intel: Top five analyst initiations
07/07/20 BofA
Vaxcyte initiated with a Buy at BofA
07/07/20 Jefferies
Vaxcyte initiated with a Buy at Jefferies
SNY Sanofi
$52.00 /

+1.19 (+2.34%)

08/10/20 SVB Leerink
Principia Biopharma price target raised to $112 from $80 at SVB Leerink
07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
SNY Sanofi
$52.00 /

+1.19 (+2.34%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

MRK Merck
$82.46 /

+1.51 (+1.87%)

  • 12
    Jun
SNY Sanofi
$52.00 /

+1.19 (+2.34%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

MRK Merck
$82.46 /

+1.51 (+1.87%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

SNY Sanofi
$52.00 /

+1.19 (+2.34%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

PCVX Vaxcyte
$37.53 /

-0.62 (-1.63%)

MRK Merck
$82.46 /

+1.51 (+1.87%)

SNY Sanofi
$52.00 /

+1.19 (+2.34%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

MRK Merck
$82.46 /

+1.51 (+1.87%)

Conference/Events
Cantor Fitzgerald biopharma analysts to hold analyst/industry conference call » 11:44
08/12/20
08/12
11:44
08/12/20
11:44
PFE

Pfizer

$38.34 /

+0.54 (+1.43%)

, MMA

Municipal Mortgage

$0.00 /

+ (+0.00%)

, AZN

AstraZeneca

$57.12 /

+1.96 (+3.55%)

, LLY

Eli Lilly

$152.02 /

+1.41 (+0.94%)

Large Cap & Biopharma…

Large Cap & Biopharma Analysts Chen & Kim, along with Key Opinion Leader Dr. Robert Kruse, of Johns Hopkins School of Medicine, discuss Pfizer vs Moderna's COVID-19 vaccine, as well as other leading vaccines in development including AstraZeneca, Eli Lilly, Oxford, on an Analyst/Industry conference call to be held on August 18 at 1 pm.

ShowHide Related Items >><<
PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
MMA Municipal Mortgage
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

Tuesday
On The Fly
Honeywell downgrade among today's top calls on Wall Street » 10:13
08/11/20
08/11
10:13
08/11/20
10:13
HON

Honeywell

$162.27 /

+2.825 (+1.77%)

, ALNY

Alnylam

$136.87 /

-1.73 (-1.25%)

, MELI

MercadoLibre

$1,141.74 /

+34.02 (+3.07%)

, ESPR

Esperion

$33.43 /

-3.55 (-9.60%)

, MSI

Motorola Solutions

$141.42 /

-0.85 (-0.60%)

Check out today's top…

Open Full Text

ShowHide Related Items >><<
MSI Motorola Solutions
$141.42 /

-0.85 (-0.60%)

MELI MercadoLibre
$1,141.74 /

+34.02 (+3.07%)

HON Honeywell
$162.27 /

+2.825 (+1.77%)

ESPR Esperion
$33.43 /

-3.55 (-9.60%)

ALNY Alnylam
$136.87 /

-1.73 (-1.25%)

HON Honeywell
$162.27 /

+2.825 (+1.77%)

08/11/20 RBC Capital
Honeywell downgraded to Sector Perform from Outperform at RBC Capital
08/11/20 RBC Capital
Honeywell downgraded to Sector Perform from Outperform at RBC Capital
07/28/20 Argus
Honeywell price target raised to $165 at Argus on continued product diversity
07/27/20 JPMorgan
Honeywell price target raised to $185 from $177 at JPMorgan
ALNY Alnylam
$136.87 /

-1.73 (-1.25%)

08/11/20 Oppenheimer
Alnylam downgraded to Perform on valuation at Oppenheimer
08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
07/20/20 BMO Capital
Alnylam price target raised to $196 from $173 at BMO Capital
06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
MELI MercadoLibre
$1,141.74 /

+34.02 (+3.07%)

08/11/20 Stifel
MercadoLibre price target raised to $1,125 from $750 at Stifel
08/11/20 BTIG
MercadoLibre price target raised to $1,260 from $980 at BTIG
08/11/20 Credit Suisse
MercadoLibre price target raised to $1,484 from $1,255 at Credit Suisse
08/11/20 Susquehanna
Susquehanna upgrades MercadoLibre as July trends accelerate
ESPR Esperion
$33.43 /

-3.55 (-9.60%)

08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
04/20/20 JMP Securities
JMP reiterates $191 price target on Esperion after Japan partnership
04/16/20 Northland
Esperion price target lowered to $42 from $60 at Northland
MSI Motorola Solutions
$141.42 /

-0.85 (-0.60%)

08/11/20
Fly Intel: Top five analyst downgrades
08/11/20 Argus
Motorola Solutions downgraded to Hold from Buy at Argus
08/11/20 Argus
Motorola Solutions downgraded to Hold from Buy at Argus
06/08/20 Barclays
Motorola Solutions price target raised to $178 from $157 at Barclays
MSI Motorola Solutions
$141.42 /

-0.85 (-0.60%)

MELI MercadoLibre
$1,141.74 /

+34.02 (+3.07%)

HON Honeywell
$162.27 /

+2.825 (+1.77%)

ESPR Esperion
$33.43 /

-3.55 (-9.60%)

ALNY Alnylam
$136.87 /

-1.73 (-1.25%)

  • 05
    Sep
MSI Motorola Solutions
$141.42 /

-0.85 (-0.60%)

MELI MercadoLibre
$1,141.74 /

+34.02 (+3.07%)

HON Honeywell
$162.27 /

+2.825 (+1.77%)

MSI Motorola Solutions
$141.42 /

-0.85 (-0.60%)

MELI MercadoLibre
$1,141.74 /

+34.02 (+3.07%)

HON Honeywell
$162.27 /

+2.825 (+1.77%)

ESPR Esperion
$33.43 /

-3.55 (-9.60%)

ALNY Alnylam
$136.87 /

-1.73 (-1.25%)

HON Honeywell
$162.27 /

+2.825 (+1.77%)

ESPR Esperion
$33.43 /

-3.55 (-9.60%)

Downgrade
Alnylam downgraded to Perform on valuation at Oppenheimer » 09:21
08/11/20
08/11
09:21
08/11/20
09:21
ALNY

Alnylam

$138.60 /

-4.82 (-3.36%)

As previously reported,…

As previously reported, Oppenheimer analyst Leland Gershell downgraded Alnylam to Perform from Outperform with a price target of $156, down from $162. While the analyst believes the broad potential of the company's RNAi platform justifies high EV/revenue multiples relative to peers, he expects limited near-term upside pending catalysts that lie sometime away.

ShowHide Related Items >><<
ALNY Alnylam
$138.60 /

-4.82 (-3.36%)

ALNY Alnylam
$138.60 /

-4.82 (-3.36%)

08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
07/20/20 BMO Capital
Alnylam price target raised to $196 from $173 at BMO Capital
06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
ALNY Alnylam
$138.60 /

-4.82 (-3.36%)

ALNY Alnylam
$138.60 /

-4.82 (-3.36%)

Hot Stocks
BridgeBio announces anticipated major milestones » 07:47
08/11/20
08/11
07:47
08/11/20
07:47
BBIO

BridgeBio

$28.43 /

+0.13 (+0.46%)

Major milestones…

Major milestones anticipated over the next 18-24 months for BridgeBio's four core value drivers: Acoramidis - TTR stabilizer for ATTR: Remain on track to complete enrollment in the Phase 3 ATTRibute-CM study in ATTR cardiomyopathy in the first half of 2021, with topline data expected in the first half of 2022. Acoramidis is a potentially best in class TTR stabilizer for ATTR-CM, a large and growing disease affecting greater than400K patients globally, and one of the first drug candidates to arise from BridgeBio's drug engineering platform. Low-dose infigratinib - FGFR1-3 inhibitor for achondroplasia: Remain on track to report initial data from the ongoing Phase 2 dose ranging study by YE2021. Achondroplasia is the most common form of genetic short stature and one of the most commonly-known genetic diseases, with greater than55K cases in the US and EU. Low-dose infigratinib is the only known therapy in development for achondroplasia that targets the disease at its genetic source and the only orally administered product candidate in clinical stage development.Encaleret - CaSR antagonist for Autosomal Dominant Hypocalcemia Type 1: Remain on track to initiate the planned Phase 2 study in 2020, with potential proof-of-concept data available in 2021. If the development program is successful, encaleret would be the first approved therapy for ADH1, a condition caused by gain of function variants in the calcium-sensing receptor gene estimated to be carried by 12k individuals in the US. BBP-631 - AAV5 gene therapy candidate for congenital adrenal hyperplasia: IND-enabling studies for AAV gene therapy proceeding. Remain on track to initiate a first in human Phase 1/2 study and report initial data in 2021. CAH is one of the most prevalent genetic diseases thought to be addressable with AAV gene therapy, with greater than75K cases in the US and EU.

ShowHide Related Items >><<
BBIO BridgeBio
$28.43 /

+0.13 (+0.46%)

BBIO BridgeBio
$28.43 /

+0.13 (+0.46%)

06/25/20 BofA
BridgeBio initiated with a Neutral at BofA
06/25/20 BofA
BridgeBio initiated with a Neutral at BofA
06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
BBIO BridgeBio
$28.43 /

+0.13 (+0.46%)

  • 29
    May
Hot Stocks
BridgeBio says 'adequately financed' through key readouts of core programs » 07:45
08/11/20
08/11
07:45
08/11/20
07:45
BBIO

BridgeBio

$28.43 /

+0.13 (+0.46%)

The company said,…

The company said, "BridgeBio remains on track with each of its four core value drivers - acoramidis for ATTR cardiomyopathy, low-dose infigratinib for achondroplasia, AAV5 gene therapy for congenital adrenal hyperplasia, and encaleret for autosomal dominant hypocalcemia type 1- and the company believes it is adequately financed through key readouts for each of these programs. Notably, BridgeBio dosed the first child in its Phase 2 clinical trial of infigratinib in achondroplasia in July."

ShowHide Related Items >><<
BBIO BridgeBio
$28.43 /

+0.13 (+0.46%)

BBIO BridgeBio
$28.43 /

+0.13 (+0.46%)

06/25/20 BofA
BridgeBio initiated with a Neutral at BofA
06/25/20 BofA
BridgeBio initiated with a Neutral at BofA
06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
BBIO BridgeBio
$28.43 /

+0.13 (+0.46%)

  • 29
    May
Earnings
BridgeBio reports Q2 EPS ($1.03), consensus (77c) » 07:44
08/11/20
08/11
07:44
08/11/20
07:44
BBIO

BridgeBio

$28.43 /

+0.13 (+0.46%)

"On a risk-adjusted…

"On a risk-adjusted basis we are in a great position to produce meaningful medicines for patients and meaningful returns to investors over the next 18 to 24 months. This is exemplified by our disease-modifying, first or best-in-class therapeutic candidates for ATTR, achondroplasia, ADH1, and CAH. We intend to deliver on this goal by expanding our industry-leading target identification and research engine and global clinical development infrastructure, and look forward to delivering our medicines, once approved, to patients through our growing commercial organization," said BridgeBio CEO and founder Neil Kumar, Ph.D.

ShowHide Related Items >><<
BBIO BridgeBio
$28.43 /

+0.13 (+0.46%)

BBIO BridgeBio
$28.43 /

+0.13 (+0.46%)

06/25/20 BofA
BridgeBio initiated with a Neutral at BofA
06/25/20 BofA
BridgeBio initiated with a Neutral at BofA
06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
BBIO BridgeBio
$28.43 /

+0.13 (+0.46%)

  • 29
    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.